Skip to search formSkip to main contentSkip to account menu

SU 11248

Known as: SU 011248, SU011248, SU11248 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

sunitinibsunitinib malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells
SU11248 is a selective inhibitor of certain protein kinases including VEGF receptors. Present study determines whether the anti… 
2007
2007
Down-Regulation of Placenta Growth Factor by Promoter Hypermethylation in Human Lung and Colon Carcinoma
Two recent clinical trials have shown that the placenta growth factor (PlGF) is up-regulated after bevacizumab treatment in… 
Review
2006
Review
2006
Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
LBA3 Background: Two multicenter phase II trials of 2nd line monotherapy with sunitinib (SU11248) in patients (pts) with mRCC… 
Highly Cited
2006
Highly Cited
2006
Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial.
7001 Background: Sunitinib malate (SU11248) is an oral, multitargeted tyrosine kinase inhibitor targeting VEGFR, PDGFR, KIT, FLT3… 
Review
2006
Review
2006
Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all?
2006
2006
A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).
4529 Background: Renal cell carcinomas are known for their vascularity and production of high levels of VEGF. Sunitinib malate… 
Highly Cited
2005
Highly Cited
2005
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
4008 Background: Standard cytotoxic chemotherapy has limited efficacy in pts with metastatic NETs. SU11248 is an oral… 
Review
2005
Review
2005
New treatments for metastatic kidney cancer.
Renal cell carcinoma accounts for approximately 3% of adult malignancies and 90%-95% of neoplasms arising from the kidney. It is… 
Highly Cited
2004
Highly Cited
2004
SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.
4500 Background: SU011248 is an oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
Highly Cited
2003
Highly Cited
2003
SU 11248 Inhibits KIT and Platelet-derived Growth Factor Receptor in Preclinical Models of Human Small Cell Lung Cancer
The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)